GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » EV-to-EBITDA

Adlai Nortye (Adlai Nortye) EV-to-EBITDA : -2.07 (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adlai Nortye's enterprise value is $159.62 Mil. Adlai Nortye's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-76.99 Mil. Therefore, Adlai Nortye's EV-to-EBITDA for today is -2.07.

The historical rank and industry rank for Adlai Nortye's EV-to-EBITDA or its related term are showing as below:

ANL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.11   Med: 0   Max: 0
Current: -2.07

ANL's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs ANL: -2.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Adlai Nortye's stock price is $6.32. Adlai Nortye's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.125. Therefore, Adlai Nortye's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Adlai Nortye EV-to-EBITDA Historical Data

The historical data trend for Adlai Nortye's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye EV-to-EBITDA Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -2.62

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - - - - -

Competitive Comparison of Adlai Nortye's EV-to-EBITDA

For the Biotechnology subindustry, Adlai Nortye's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adlai Nortye's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's EV-to-EBITDA falls into.



Adlai Nortye EV-to-EBITDA Calculation

Adlai Nortye's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=159.617/-76.988
=-2.07

Adlai Nortye's current Enterprise Value is $159.62 Mil.
Adlai Nortye's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adlai Nortye  (NAS:ANL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Adlai Nortye's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.32/-2.125
=At Loss

Adlai Nortye's share price for today is $6.32.
Adlai Nortye's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.125.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Adlai Nortye EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adlai Nortye (Adlai Nortye) Business Description

Traded in Other Exchanges
Address
685 US Highway 1, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. The company has robust pipeline of drug candidates it includes buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.

Adlai Nortye (Adlai Nortye) Headlines